Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients

MT Newswires Live

06/11

Kura Oncology (KURA) and Kyowa Kirin reported long-term data showing high remission rates and favorable survival outcomes for ziftomenib in combination with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia, the companies said Thursday.

Among NPM1-mutated patients, the combination achieved a 96% composite complete remission rate and a 94% estimated overall survival rate at 12 months.. Patients with KMT2A-rearranged AML achieved a 90% composite complete remission rate and a 71% 12 month overall survival rate, according to the companies.

The treatment maintained a consistent and manageable safety profile, with no new safety signals identified during extended follow-up, the companies said.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2642282683"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2642282683\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2642282683?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642282683","market":"sg","top_or_hot":-1,"title":"Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/KURA\">Kura Oncology</a> (KURA) and Kyowa Kirin reported long-term data showing high remission rates and favorable survival outcomes for ziftomenib in combination with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia, the companies said Thursday.</p><p>Among NPM1-mutated patients, the combination achieved a 96% composite complete remission rate and a 94% estimated overall survival rate at 12 months.. Patients with KMT2A-rearranged AML achieved a 90% composite complete remission rate and a 71% 12 month overall survival rate, according to the companies.</p><p>The treatment maintained a consistent and manageable safety profile, with no new safety signals identified during extended follow-up, the companies said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-11 20:55</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/KURA\">Kura Oncology</a> (KURA) and Kyowa Kirin reported long-term data showing high remission rates and favorable survival outcomes for ziftomenib in combination with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia, the companies said Thursday.</p><p>Among NPM1-mutated patients, the combination achieved a 96% composite complete remission rate and a 94% estimated overall survival rate at 12 months.. Patients with KMT2A-rearranged AML achieved a 90% composite complete remission rate and a 71% 12 month overall survival rate, according to the companies.</p><p>The treatment maintained a consistent and manageable safety profile, with no new safety signals identified during extended follow-up, the companies said.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KURA","symbol_name":"Kura Oncology, Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642282683","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642282683","pubTimestamp":1781182501,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kura Oncology  and Kyowa Kirin reported long-term data showing high remission rates and favorable survival outcomes for ziftomenib in combination with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia, the companies said Thursday.Among NPM1-mutated patients, the combination achieved a 96% composite complete remission rate and a 94% estimated overall survival rate at 12 months.. Patients with KMT2A-rearranged AML achieved a 90% composite complete remission rate and a 71% 12 month overall survival rate, according to the companies.The treatment maintained a consistent and manageable safety profile, with no new safety signals identified during extended follow-up, the companies said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KURA":"Kura Oncology, Inc","BK4139":"生物科技","BK4505":"高瓴资本持仓"},"translate_title":"Kura Oncology、Kyowa Kirin癌症组合疗法延长AML患者生存期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURA":1.5},"content_text":"Kura Oncology (KURA) and Kyowa Kirin reported long-term data showing high remission rates and favorable survival outcomes for ziftomenib in combination with intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia, the companies said Thursday.Among NPM1-mutated patients, the combination achieved a 96% composite complete remission rate and a 94% estimated overall survival rate at 12 months.. Patients with KMT2A-rearranged AML achieved a 90% composite complete remission rate and a 71% 12 month overall survival rate, according to the companies.The treatment maintained a consistent and manageable safety profile, with no new safety signals identified during extended follow-up, the companies said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}